An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update)

Abstract

Background: The efficacy and tolerability of insulin detemir (detemir), a long-acting basal insulin analog, is already well documented for type 1 diabetes. This article reviews new evidence, in particular on the weight-sparing effect of detemir and its use in type 2 diabetes. Methods: All clinical trials of detemir published since a 2006 drug evaluation and up to December 2007, including large real-life studies, are covered in this review. Earlier studies are cited when relevant. Results/conclusion: In type 2 diabetes, detemir used once or twice daily achieves equivalent glycemic control to other basal insulins in treat-to-target trials but tends to improve control in patients switched from other basal insulins in basal–oral regimens. The risk of hypoglycemia (nocturnal, overall, or both) is substantially and significantly reduced with detemir compared with NPH insulin. Body weight increase is consistently significantly lower with detemir than with NPH in type 1 and type 2 diabetes. The results of both glucose clamp studies and clinical trials support initiation of detemir at a once-daily dosing regimen.

Keywords::

• basal insulin
• basal–oral therapy
• hypoglycemia
• insulin detemir
• type 2 diabetes
• weight

Acknowledgements

The author would like to thank Watermeadow Medical, Witney, UK for their assistance in the preparation of this manuscript, which was supported by Novo Nordisk.

Notes